- Tags: MIGSglaucoma
Pipeline
FDA accepts Nicox's NDA for IOP-lowering glaucoma drop
PDUFA target action date of April 30, 2027, is set for the newly-renamed K-911, a nitric oxide-donating bimatoprost formulation.
Research
New research confirms association of OSA with glaucoma
Real-world cohort study indicates patients with obstructive sleep apnea may have a higher long-term risk of developing glaucoma.
Research
Side sleepers face higher risk of uneven glaucoma
Reduced ONH blood flow in the dependent eye during side sleeping may help explain asymmetric damage in patients with obstructive sleep apnea.
Pipeline
Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study
US 510(k) study to evaluate glaucoma drainage device for IOP reduction among OAG patients who failed previous medical and surgical treatment.
Pipeline
Kowa submits NDA for NCX 470, a IOP-lowering glaucoma drop
Pending FDA review, Nicox’s NO-donating bimatoprost formulation could receive approval and commercially launch by the end of 2027.
Research
Glaucoma risk higher among women with postmenopausal HRT
Postmenopausal hormone therapy may be linked to higher glaucoma risk, with registry data suggesting the association holds across hormone types.
Products
Thea Pharma's ZOLYMBUS ophthalmic gel launches for glaucoma management
The PF formulation debuts 9 months after securing FDA approval with a patented mucoadhesive lubricating gel technology for IOP reduction.
Research
Should normal-tension glaucoma patients be more closely monitored?
New research suggests certain NTG patients may need closer follow-up due to unstable visual field results.
Products
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System
AMA approves application in conjunction with Category I cataract surgery codes; applies to investigational bimatoprost delivery system for IOP reduction in OAG and OHT.
Products
FDA clears Balance Ophthalmics' wireless-enabled IOP device for glaucoma
Next-generation iteration of the portable IOP-lowering system delivers patient usage data to clinical practices from nighttime monitoring.
Events
Registration opens for Eyes On Glaucoma 2026
The largest virtual glaucoma event of the year offers up to 5 hours of free CE from leading clinical experts in the industry.
Business
Bayer to acquire Perfuse Therapeutics, expanding ophthalmic pipeline
Deal includes the biotech’s investigational sustained-release implant currently in phase 2 clinical trials for glaucoma and diabetic retinopathy.
Products
Iantrek introduces AlloSpan Canal to its bio-interventional platform
Tech combines nitinol-guided canaloplasty with allogeneic biological scaffolding to restore and maintain Schlemm’s canal—without leaving synthetic hardware in the eye.
Research
Study: Smoking an unlikely risk factor for glaucoma
While the association between smoking and glaucoma was weak, smoking cessation remains important for well-being.
Research
IRIS Registry data analysis predicts goniotomy success rates
Study identifies new factors that predict successful outcomes following goniotomy.
Research
Skipping nighttime pillows may lower IOP for glaucoma patients
Study finds high-pillow position was associated with greater IOP fluctuation and jugular venous compression.
Research
Smart contact lens performs real-time IOP monitoring
New smart contact lens design demonstrates potential for long-term, non-invasive IOP monitoring for glaucoma patients.
Business
Avisi raises $10.7M to advance study on VisiPlate glaucoma device
Financing to support IDE-approved study evaluating the novel minimally-invasive bleb surgery shunt for lowering IOP via aqueous drainage control.
Events
AGS 2026 highlights best practices for surgery and new, evidence-based innovations
Did you miss the 2026 American Glaucoma Society (AGS) annual meeting? Not to worry—we've got the highlights.
Pipeline